Mefloquine, a new type of compound against schistosomes and other helminthes in experimental studies

被引:27
作者
Xiao, Shu-hua [1 ]
机构
[1] WHO Collaborating Ctr Malaria Schistosomiasis & F, Chinese Ctr Dis Control & Prevent, Key Lab Parasite & Vector Biol, Natl Inst Parasit Dis,MOH, Shanghai 200025, Peoples R China
关键词
MICE FOLLOWING TREATMENT; IN-VITRO; ANTISCHISTOSOMAL DRUGS; SYNTHETIC TRIOXOLANES; DIFFERENT AGES; CURE RATES; PRAZIQUANTEL; MANSONI; JAPONICUM; CHEMOTHERAPY;
D O I
10.1007/s00436-013-3559-0
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Up to date, schistosomiasis is still prevalent worldwide. It is estimated that more than 200 million individuals are infected, and 120 million suffer from clinical morbidity. Facing such huge cases of schistosomiasis, only heavy reliance on a single praziquantel for schistosomiasis control does not adapt and may promote the selection and spread of drug-resistant parasites. Therefore, it is an urgent need to develop the new antischistosomal drug. In 2008-2009, the antimalarial drug mefloquine, an arylaminoalcohol compound, has been found to be effective against schistosomes. According to the experimental studies, the deepest impression on the antischistosomal properties of mefloquine can be summarized as following points: (1) single dose of mefloquine possesses potential effect against three major species of schistosomes (Schistosoma mansoni, Schistosoma haematobium, and Schistosoma japonicum) infecting humans; (2) the drug displays similar effects against developing stages of juvenile and adult schistosomes, which are superior to that of artemisinins and praziquantel; (3) in vitro mefloquine exerts direct killing effect on juvenile and adult schistosomes, while in vivo, the efficacy of the drug is independent to host immune response, (4) mefloquine causes extensive and severe morphological, histopathological, and ultrastructural damage to adult and juvenile schistosomes, particularly, the worm tegument, musculature, gut, and vitelline glands of female worms are the key sites attacked by the drug; (5) combined treatment with mefloquine and praziquantel, or artemisinins shows synergistic effect against schistosome in experimental therapy,while in initially clinical trial, mefloquine in combination with artesunate also exhibits higher cure rates against schistosomiasis hematobia and schistosomiasis mansoni, and (6) several mefloquine-related arylmethanols exhibit potential effect against schistosomes in vivo, which is a useful clue helpful for development of new antischistosomal compound. In the present review, we have summarized the major results published in recent years, and the significance as well as the prospect for the future study of mefloquine have been discussed briefly.
引用
收藏
页码:3723 / 3740
页数:18
相关论文
共 69 条
[1]   Schistosomiasis mansoni: Novel chemotherapy using a cysteine protease inhibitor [J].
Abdulla, Maha-Hamadien ;
Lim, Kee-Chong ;
Sajid, Mohammed ;
McKerrow, James H. ;
Caffrey, Conor R. .
PLOS MEDICINE, 2007, 4 (01) :130-138
[2]   A study of the activity of 2-(alkylamino)-1-phenyl-1-ethanethiosulfuric acids against infection by Schistosoma mansoni in a murine model [J].
Alves Moreira, Liliani Salum ;
Pilo-Veloso, Dorila ;
de Mello, Romulo Teixeira ;
Zech Coelho, Paulo Marcos ;
Nelson, David Lee .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2007, 101 (04) :385-390
[3]   Efficacy of Mefloquine Intermittent Preventive Treatment in Pregnancy Against Schistosoma haematobium Infection in Gabon: A Nested Randomized Controlled Assessor-Blinded Clinical Trial [J].
Basra, Arti ;
Mombo-Ngoma, Ghyslain ;
Melser, Meskure Capan ;
Diop, Daisy Akerey ;
Wuerbel, Heike ;
Mackanga, Jean-Rodolphe ;
Fuerstenau, Moritz ;
Zoleko, Rella Manego ;
Adegnika, Ayola A. ;
Gonzalez, Raquel ;
Menendez, Clara ;
Kremsner, Peter G. ;
Ramharter, Michael .
CLINICAL INFECTIOUS DISEASES, 2013, 56 (06) :E68-E75
[4]   Impact of intense, longitudinal retreatment with praziquantel on cure rates of schistosomiasis mansoni in a cohort of occupationally exposed adults in western Kenya [J].
Black, Carla L. ;
Steinauer, Michelle L. ;
Mwinzi, Pauline N. M. ;
Secor, W. Evan ;
Karanja, Diana M. S. ;
Colley, Daniel G. .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2009, 14 (04) :450-457
[5]   Activity of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine against Schistosomiasis mansoni in Mice [J].
Botros, S ;
William, S ;
Hammam, L ;
Zídek, Z ;
Holy, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (12) :3853-3858
[6]  
BRINDLEY PJ, 1987, J IMMUNOL, V139, P215
[7]   Chemotherapy of schistosomiasis: present and future [J].
Caffrey, Conor R. .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2007, 11 (04) :433-439
[8]   Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years' experience [J].
Chen, MG .
ACTA TROPICA, 2005, 96 (2-3) :168-176
[9]   Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal [J].
Danso-Appiah, A ;
De Vlas, SJ .
TRENDS IN PARASITOLOGY, 2002, 18 (03) :125-129
[10]   Artemisinin-based combination therapies for uncomplicated malaria [J].
Davis, TME ;
Karunajeewa, HA ;
Ilett, KF .
MEDICAL JOURNAL OF AUSTRALIA, 2005, 182 (04) :181-185